PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for July 26, 2002 Subscribe to this News Feed    
 

IIR Industry Alert: Patheon Expands Pharma-Biotech Manufacturing Capacity in Italy

With approximately 2,700 employees and over 100 pharmaceutical and biotechnology clients, Patheon is striving to become the preferred contract manufacturer for the industry.

HOUSTON-July 25, 2002-Researched by Industrialinfo.com (Industrial Information Resources, Incorporated; Houston, Texas). Patheon Incorporated (TSE: PTI) (Mississauga, Ontario) purchased the Ferentino, Italy facility from Biomedica Foscama SpA (Ferentino, Italy) in February 2002. Patheon is spending approximately $40 million on upgrading the idled facility this year.

For project and company details view the entire article at www.industrialinfo.com.

Established in 1983, Industrial Information Resources Inc. (IIR) is a leading source for industrial market information covering the industrial process, manufacturing, and energy related markets. IIR tracks project spending trends in the Pharmaceutical-Biotech industry and has recently released the 2002 U.S. Pharmaceutical-Biotech Forecast. For more information on trends and upcoming construction activities in the Pharmaceutical-Biotech markets as well as other industrial sectors send inquiries to pharmabiogroup@industrialinfo.com or visit us at www.industrialinfo.com.

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Mike Bergen
Industrial Information Resources
713-783-5147
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.